Literature DB >> 23007558

Cellular and molecular mechanisms of hepatocellular carcinoma: an update.

Rajagopal N Aravalli1, Erik N K Cressman, Clifford J Steer.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor that accounts for ~80 % of all liver cancer cases worldwide. It is a multifactorial disease caused by a variety of risk factors and often develops in the background of underlying cirrhosis. A number of cellular phenomena, such as tumor microenvironment, inflammation, oxidative stress, and hypoxia act in concert with various molecular events to facilitate tumor initiation, progression, and metastasis. The emergence of microRNAs and molecular-targeted therapies adds a new dimension in our efforts to combat this deadly disease. Intense research in this multitude of areas has led to significant progress in our understanding of cellular processes and molecular mechanisms that occur during multistage events that lead to hepatocarcinogenesis. In this review, we discuss the current knowledge of HCC, focusing mainly on advances that have occurred during the past 5 years and on the development of novel therapeutics for liver cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007558     DOI: 10.1007/s00204-012-0931-2

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  90 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

2.  Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression.

Authors:  Laila H Faraj Shaglouf; Maryam Ranjpour; Saima Wajid; Swatantra Kumar Jain
Journal:  Protoplasma       Date:  2019-08-19       Impact factor: 3.356

Review 3.  Radiofrequency electromagnetic radiation-induced behavioral changes and their possible basis.

Authors:  Sareesh Naduvil Narayanan; Raghu Jetti; Kavindra Kumar Kesari; Raju Suresh Kumar; Satheesha B Nayak; P Gopalakrishna Bhat
Journal:  Environ Sci Pollut Res Int       Date:  2019-08-28       Impact factor: 4.223

Review 4.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

5.  The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma.

Authors:  Takeki Uehara; Igor P Pogribny; Ivan Rusyn
Journal:  Curr Protoc Pharmacol       Date:  2014-09-02

6.  Silibinin Inhibits Proliferation and Migration of Human Hepatic Stellate LX-2 Cells.

Authors:  Devaraj Ezhilarasan; Jonathan Evraerts; Sid Brice; Pedro Buc-Calderon; Sivanesan Karthikeyan; Etienne Sokal; Mustapha Najimi
Journal:  J Clin Exp Hepatol       Date:  2016-01-13

7.  Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1.

Authors:  Hyang Sook Seol; Sang Eun Lee; Joon Seon Song; Je-Keun Rhee; Shree Ram Singh; Suhwan Chang; Se Jin Jang
Journal:  Cancer Lett       Date:  2015-12-23       Impact factor: 8.679

8.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

9.  Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis.

Authors:  Senjun Zhou; Jiliang Shen; Shuang Lin; Xiaolong Liu; Ming Xu; Liang Shi; Xianfa Wang; Xiujun Cai
Journal:  Tumour Biol       Date:  2016-07-28

10.  Effects of melatonin on HIF-1α and VEGF expression and on the invasive properties of hepatocarcinoma cells.

Authors:  Jucimara Colombo; João Marcos Wolf Maciel; Lívia Carvalho Ferreira; Renato Ferreira DA Silva; Debora Aparecida Pires Zuccari
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.